Clearmind Medicine CMND 深 滬
等待開盤 09-17 09:30:00 美东时间
0.8059
-0.058
-6.76%
華盛通- 最 高0.8469
- 今 開0.841
- 成交量 15.36万股
- 最 低 0.79
- 昨 收 0.8643
- 總市值 271.35万
- 52周最高 480.00
- 市盈率 靜 --
- 換手率 4.56%
- 52周最低 0.79
- 委 比 83.82%
- 總股本 336.71万
- 歷史最高 73200.00
- 量 比 0.72
- 振 幅 6.58%
- 歷史最低 0.79
- 每 手 1
- 風險率 138.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Inc. announced the enrollment of the first AUD patients in its CMND-100 clinical trial, marking a significant milestone in its neuroplastogen-based treatment development.
09-11 12:00
Clearmind Medicine Inc. GAAP EPS of -$0.57
Clearmind Medicine Inc. press release (CMND): Q3 GAAP EPS of -$0.57. More on Clearmind Medicine Inc. Clearmind Medicine signs agreement to acquire 51% stake in Charging Robotics Financial information ...
09-11 04:19
Clearmind Medicine Stock Slides Friday: What's Happening?
Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are trading lower Friday morning as investors digest news of the clinical-stage biotech company expanding beyond its core pharmaceutical focus to acquire a majority stake in an electric vehicle charging firm. Clearmind Medicine shares are sliding. What...
09-04 20:59
Clearmind Medicine signs agreement to acquire 51% stake in Charging Robotics
Clearmind Medicine (CMND) on Friday said it has entered into a definitive agreement to acquire a 51% stake in Charging Robotics, an EV wireless charging firm for automated parking and robotaxis. Under...
09-04 19:39
Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD
Clearmind Medicine Inc. (NASDAQ:CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today th...
09-01 19:38
Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder
Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical company advancing non-hallucinogenic, psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders, including AUD, today announced an advancement of its IP portfolio...
08-24 20:07
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Clearmind Medicine Inc. announced the publication of a U.S. patent application covering a novel combination of MDMA and N-acylethanolamines, such as PEA, for treating PTSD, anxiety, and eating disorders. This milestone stems from its collaboration with NeuroThera Labs Inc., contributing to a growing intellectual property portfolio with 13 patent applications. The new application highlights PEA's potential to enhance MDMA's therapeutic effects, re...
08-24 12:03
Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder
All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in AUD patients. "We are pleased to ...
07-28 19:49
Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demonstrated Markedly Improved Nasal Residence Characteristics Compared With Standard MEAI Solution
Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy of developing differentiated, next‑generation treatments for AUD and other high‑need indications. The study forms a core component of Clearmind’s intr...
07-16 21:32
Clearmind Medicine Announces Progress In Evaluating Intranasal Delivery Of Its Proprietary MEAI Treatment For Alcohol Use Disorder
The program is evaluating intranasal delivery of MEAI as a potential additional route of administration, with initial studies focused on assessing formulation feasibility and supporting the continued development of this delivery approach. AUD remains a significant unmet medical need worldwide, affec...
07-07 19:45
